CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study

Area of Science:

• Immunology
• Pulmonology
• Pharmacology

Background:

• Asthma treatment requires new options for patients uncontrolled by current inhaled therapies.
• A previous Phase 2a trial showed CYT003 improved asthma control during glucocorticosteroid reduction.
• This Phase 2b study evaluated CYT003 in moderate-to-severe allergic asthma patients uncontrolled by standard inhaled therapies.

Purpose of the Study:

• To assess the efficacy and safety of CYT003 as an add-on therapy.
• To determine if CYT003 offers additional benefit beyond standard inhaled glucocorticosteroids and long-acting beta-agonists (LABAs).

Main Methods:

• 365 patients received subcutaneous CYT003 (0.3, 1, or 2 mg) or placebo.
• The primary outcome was the change in Asthma Control Questionnaire (ACQ) score from baseline.
• Secondary outcomes included lung function (forced expiratory volume) and quality of life.

Main Results:

• No significant difference in ACQ score improvement was observed between CYT003 and placebo groups at week 12.
• Secondary outcomes also showed no significant differences.
• CYT003 was well tolerated, with injection site reactions being the most common adverse event.

Conclusions:

• Toll-like receptor-9 agonism with CYT003 did not provide additional benefit for patients with inadequately controlled moderate-to-severe allergic asthma.
• The study was terminated early due to lack of efficacy.
• New therapeutic strategies are needed for this patient population.